brand logo

Am Fam Physician. 2023;108(3):online

Author disclosure: No relevant financial relationships.

Details for This Review

Study Population: 45,049 adult tobacco smokers who were willing to quit; varenicline (Chantix) studies were conducted in the United States and other countries, whereas cytisine studies were conducted in countries other than the United States; all studies were conducted in middle- and high-income countries and included inpatient and various outpatient settings

Efficacy End Points: Smoking abstinence at longest follow-up (six months or more)

Harm End Points: Serious adverse events, neuropsychiatric serious adverse events, and cardiac serious adverse events

Cytisine (not available in the United States) vs. placebo
1 in 22 was abstinent from smoking at longest follow-up (six months or more)No significant difference in rates of serious adverse events
Varenicline (Chantix) vs. placebo
1 in 8 was abstinent from smoking at longest follow-up (six months or more)1 in 166 experienced serious adverse events
Already a member/subscriber?  Log In


From $165
  • Immediate, unlimited access to all AFP content
  • More than 130 CME credits/year
  • AAFP app access
  • Print delivery available

Issue Access

  • Immediate, unlimited access to this issue's content
  • CME credits
  • AAFP app access
  • Print delivery available
Purchase Access:  Learn More

Copyright ©2024 MD Aware, LLC ( Used with permission.

This series is coordinated by Christopher W. Bunt, MD, AFP assistant medical editor, and the NNT Group.

A collection of Medicine by the Numbers published in AFP is available at https://

Continue Reading

More in AFP

More in PubMed

Copyright © 2023 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.